MA26730A1 - Composes nouveaux antagonistes de npy, procede pour leur preparation et compositions pharmaceutiques les contenant - Google Patents

Composes nouveaux antagonistes de npy, procede pour leur preparation et compositions pharmaceutiques les contenant

Info

Publication number
MA26730A1
MA26730A1 MA25963A MA25963A MA26730A1 MA 26730 A1 MA26730 A1 MA 26730A1 MA 25963 A MA25963 A MA 25963A MA 25963 A MA25963 A MA 25963A MA 26730 A1 MA26730 A1 MA 26730A1
Authority
MA
Morocco
Prior art keywords
preparation
pharmaceutical compositions
compositions containing
antagonist compounds
npy antagonist
Prior art date
Application number
MA25963A
Other languages
English (en)
Inventor
Louis Elliott Richard
Frederick Hank Richard
Hammond Marlys
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of MA26730A1 publication Critical patent/MA26730A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
MA25963A 1999-04-30 2000-04-26 Composes nouveaux antagonistes de npy, procede pour leur preparation et compositions pharmaceutiques les contenant MA26730A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13202999P 1999-04-30 1999-04-30

Publications (1)

Publication Number Publication Date
MA26730A1 true MA26730A1 (fr) 2004-12-20

Family

ID=22452122

Family Applications (1)

Application Number Title Priority Date Filing Date
MA25963A MA26730A1 (fr) 1999-04-30 2000-04-26 Composes nouveaux antagonistes de npy, procede pour leur preparation et compositions pharmaceutiques les contenant

Country Status (12)

Country Link
US (2) US6355635B1 (fr)
AR (1) AR028824A1 (fr)
AU (1) AU2935200A (fr)
CO (1) CO5170414A1 (fr)
GT (1) GT200000057A (fr)
HN (1) HN2000000041A (fr)
MA (1) MA26730A1 (fr)
PA (1) PA8493701A1 (fr)
PE (1) PE20010118A1 (fr)
TN (1) TNSN00092A1 (fr)
UY (1) UY26130A1 (fr)
WO (1) WO2000066578A1 (fr)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR032292A1 (es) 1999-12-16 2003-11-05 Schering Corp Imidazoles sustituidos, composiciones farmaceuticas y el uso de dichos imidazoles para la manufactura de un medicamento para los tratamientos de desordenes en la alimentacion
US6894063B2 (en) * 2000-09-14 2005-05-17 Schering Corporation Substituted urea neuropeptide Y Y5 Receptor antagonists
US20050043256A1 (en) * 2001-07-30 2005-02-24 Isis Pharmaceuticals, Inc. Antisense modulation of stearoyl-CoA desaturase expression
CA2469790A1 (fr) * 2001-12-17 2003-06-26 Merck & Co., Inc. Traitement des ruptures du rythme circadien
CN1628109A (zh) * 2002-02-05 2005-06-15 诺沃挪第克公司 新颖的芳基－与杂芳基－哌嗪
JP3813152B2 (ja) 2002-03-12 2006-08-23 メルク エンド カムパニー インコーポレーテッド 置換アミド類
MXPA05004115A (es) * 2002-10-18 2005-06-22 Pfizer Prod Inc Ligandos del receptor cannabionoide y usos de los mismos.
WO2005000217A2 (fr) * 2003-06-06 2005-01-06 Merck & Co., Inc. Polytherapie permettant de traiter la dyslipidemie
AU2004259263B2 (en) 2003-07-29 2010-12-16 High Point Pharmaceuticals, Llc Pyridazinyl- piperazines and their use as histamine H3 receptor ligands
MXPA06003380A (es) * 2003-09-26 2006-06-08 Pfizer Prod Inc Uso de antagonista del receptor npy y5 para el tratamiento de trastornos del ritmo circadiano.
JP2007506731A (ja) * 2003-09-26 2007-03-22 ファイザー・プロダクツ・インク Ｎｐｙｙ５受容体アンタゴニストによる急速眼球運動（ｒｅｍ）睡眠妨害に関連する神経障害の治療
US7319108B2 (en) 2004-01-25 2008-01-15 Sanofi-Aventis Deutschland Gmbh Aryl-substituted heterocycles, process for their preparation and their use as medicaments
DE102004003812A1 (de) * 2004-01-25 2005-08-11 Aventis Pharma Deutschland Gmbh Arylsubstituierte Heterozyklen, Verfahren ihrer Herstellung und ihre Verwendung als Arzneimittel
US20050256124A1 (en) * 2004-04-15 2005-11-17 Neurocrine Biosciences, Inc. Melanin-concentrating hormone receptor antagonists and compositions and methods related thereto
US20060039890A1 (en) * 2004-08-20 2006-02-23 Renshaw Perry F Treatment of psychological and cognitive disorders using a cholesterol -lowering agent in combination with an antidepressant
TW200626138A (en) 2004-09-20 2006-08-01 Xenon Pharmaceuticals Inc Heterocyclic derivatives and their use as therapeutic agents
WO2006034341A2 (fr) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Derives heterocycliques et leur utilisation en tant qu'agents therapeutiques
AR051026A1 (es) 2004-09-20 2006-12-13 Xenon Pharmaceuticals Inc Derivados heterociclicos y su uso como inhibidores de la estearoil-coa desaturasa
BRPI0515482A (pt) 2004-09-20 2008-07-22 Xenon Pharmaceuticals Inc derivados heterocìclicos e seus usos como agentes terapêuticos
MX2007003327A (es) 2004-09-20 2007-06-05 Xenon Pharmaceuticals Inc Derivados heterociclicos, y su uso como mediadores de estearoil-coa desaturasa.
US8071603B2 (en) 2004-09-20 2011-12-06 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors
CA2580855A1 (fr) * 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Derives heterocycliques et leur utilisation en tant qu'agents therapeutiques
CA2577821A1 (fr) * 2004-09-24 2006-04-06 Merck & Co., Inc. Therapie combinatoire dans le traitement de l'obesite
GB0510141D0 (en) * 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds B3
US8541457B2 (en) 2005-06-03 2013-09-24 Xenon Pharmaceuticals Inc. Aminothiazole derivatives as human stearoyl-CoA desaturase inhibitors
MX2007015675A (es) 2005-07-04 2008-02-20 Novo Nordisk As Antagonistas del receptor de histamina h3.
AU2006331656B2 (en) * 2005-12-22 2012-08-09 Icagen, Inc. Calcium channel antagonists
CA2653062A1 (fr) * 2006-05-23 2007-11-29 Transtech Pharma, Inc. Nouveaux medicaments
KR20090040259A (ko) 2006-05-29 2009-04-23 하이 포인트 파마슈티칼스, 엘엘씨 3-(1,3-벤조디옥솔-5-일)-6-(4-시클로프로필피페라진-1-일)-피리다진, 그것의 염과 용매화합물 및 그것의 히스타민 ｈ3 수용체 안타고니스트로서의 용도
WO2008033575A2 (fr) * 2006-09-15 2008-03-20 Metabolon, Inc. Procédés d'identification de cheminements biochimiques
NZ580454A (en) * 2007-03-16 2011-05-27 Actelion Pharmaceuticals Ltd Amino- pyridine derivatives as s1p1 /edg1 receptor agonists
EP2014656A3 (fr) 2007-06-11 2011-08-24 High Point Pharmaceuticals, LLC Nouveaux antagonistes d'hétéocycliques h3
WO2009112033A1 (fr) * 2008-03-12 2009-09-17 Københavns Universitet (University Of Copenhagen) Utilisation d’antagonistes de récepteur npy y5 pour la prévention de l’abus de psychostimulants et d’opioïdes
BRPI0922364A2 (pt) 2008-12-03 2017-08-29 Presidio Pharmaceuticals Inc Composto, composição farmacêutica e uso de um composto
WO2012081736A1 (fr) 2010-12-17 2012-06-21 Mitsubishi Tanabe Pharma Corporation Composé arycyclique continu
WO2013187496A1 (fr) 2012-06-15 2013-12-19 田辺三菱製薬株式会社 Composé hétérocyclique aromatique
WO2016105491A1 (fr) * 2014-12-23 2016-06-30 Fgh Biotech Compositions de composés hétérocycliques à base de fatostatine et utilisations associées
EP4368184A3 (fr) * 2019-11-19 2024-07-31 Modag GmbH Nouveaux composés pour le diagnostic, le traitement et la prévention de maladies associées à l'agrégation de l'alpha-synucléine

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4440774A (en) 1975-03-03 1984-04-03 Merck & Co., Inc. 3-Amino-2-hydroxypropoxyaryl imidazole derivatives
US4853383A (en) 1975-03-03 1989-08-01 Merck & Co., Inc. β-blocking substituted imidazoles
JPH0251150A (ja) * 1988-08-12 1990-02-21 Konica Corp 新規なシアンカプラーを含有するハロゲン化銀写真感光材料
DE3935514A1 (de) * 1989-10-25 1991-05-02 Boehringer Mannheim Gmbh Neue bicyclo-imidazole, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
DE59006842D1 (de) * 1990-03-30 1994-09-22 Heumann Pharma Gmbh & Co Verwendung von Guanidinderivaten zur Herstellung eines Arzneimittels mit NPY-antagonistischer Wirkung.
US6562862B1 (en) 1994-10-20 2003-05-13 Eli Lilly And Company Methods of inhibiting physiological conditions associated with an excess of neuropeptide Y
BR9509610A (pt) 1994-11-07 1997-10-28 Pfizer Ligandos específicos de neuropeptideo Y1
EP0759441A3 (fr) * 1995-06-30 1999-06-30 Eli Lilly And Company Procédés de traitement des pathologies associées aux peptides neuropeptide Y
EP0996443A1 (fr) * 1997-07-03 2000-05-03 Neurogen Corporation Certains derives diarylimidazoles; nouvelle classe de ligands specifiques de neuropeptide y (npy)
JP2002507603A (ja) * 1998-03-25 2002-03-12 ブリストル−マイヤーズ スクイブ カンパニー イミダゾロン食欲抑制薬：ｉ．非環式誘導体

Also Published As

Publication number Publication date
PE20010118A1 (es) 2001-02-03
WO2000066578A1 (fr) 2000-11-09
AR028824A1 (es) 2003-05-28
PA8493701A1 (es) 2002-07-30
UY26130A1 (es) 2000-12-29
US6355635B1 (en) 2002-03-12
US20010039277A1 (en) 2001-11-08
GT200000057A (es) 2001-10-20
US6514966B2 (en) 2003-02-04
CO5170414A1 (es) 2002-06-27
TNSN00092A1 (fr) 2005-11-10
HN2000000041A (es) 2001-02-02
AU2935200A (en) 2000-11-17

Similar Documents

Publication Publication Date Title
MA26730A1 (fr) Composes nouveaux antagonistes de npy, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26712A1 (fr) Derives bicycliques substitues nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
FR2780057B1 (fr) Phenoxypropanolamines, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26622A1 (fr) Pyrazolopyrimidinones nouvelles, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26740A1 (fr) Derives de 13-methyl-erythromycine nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26743A1 (fr) Composes nouveaux inhibiteurs de metalloproteases, procede pour leur preparation et compositions pharmaceutiques les contenant
FR2729951B1 (fr) Nouveaux composes heterocycliques, procede pour leur preparation et compositions pharmaceutiques en contenant
MA26687A1 (fr) 4-carboxyamino-2-methyl-1,2,3,4-tetrahydroquinoleines, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26680A1 (fr) Derives de quinoleine-2-one a substituant alcynyle nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26686A1 (fr) Derives de 4,4-biarylpiperidine nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
FR2827604B1 (fr) Nouveaux derives de 1-phenylsulfonyl-1,3-dihydro-2h-indol-2- one, un procede pour leur preparation et les compositions pharmaceutiques en contenant
MA26611A1 (fr) Composes heterocycliques nouveaux inhibiteurs de romatases, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26669A1 (fr) 1-aryl-3-arylmethyl-1,8-naphtyridine-4(1h)-ones nouvelles, procede pour leur preparation et compositions pharmaceutiques les contenant
FR2794742B1 (fr) Nouveaux derives du benzene, un procede pour leur preparation et les compositions pharmaceutiques les contenant
DZ3000A1 (fr) Macrolides nouveaux, procédé pour leur préparationet compositions pharmaceutiques les contenant.
MA26465A1 (fr) Derives de quinoleine et derives de quinazoline nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26624A1 (fr) Derives de quinazolinamines nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26707A1 (fr) Azalides nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant.
FR2805536B1 (fr) Nouveaux derives de 1,3-dihydro-2h-indol-2-one, un procede pour leur preparation et les compositions pharmaceutiques en contenant
MA26501A1 (fr) Derives de quinoleine nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26642A1 (fr) Derives de sulfonylbenzene nouveaux, procédé pour leur preparation et compositions pharmaceutiques les contenant.
MA26619A1 (fr) Composes azabicycliques substitues nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26597A1 (fr) Polysaccharides de synthese, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26631A1 (fr) Composes a fonction bis-aminomethyl-carbonyle nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26594A1 (fr) Composes nouveaux inhibiteurs de mmp, procede pour leur preparation et compositions pharmaceutiques les contenant